Suppr超能文献

相似文献

1
Molecular mechanisms involved in dendritic cell dysfunction in cancer.
Cell Mol Life Sci. 2017 Mar;74(5):761-776. doi: 10.1007/s00018-016-2317-8. Epub 2016 Aug 5.
2
Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy.
Pharmacol Res. 2020 Sep;159:104980. doi: 10.1016/j.phrs.2020.104980. Epub 2020 Jun 3.
3
Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy.
Front Immunol. 2018 Dec 5;9:2759. doi: 10.3389/fimmu.2018.02759. eCollection 2018.
4
Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside.
Life Sci. 2022 May 15;297:120466. doi: 10.1016/j.lfs.2022.120466. Epub 2022 Mar 7.
5
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy.
Cancer Commun (Lond). 2024 Sep;44(9):1047-1070. doi: 10.1002/cac2.12596. Epub 2024 Jul 25.
6
Dendritic cell biology and its role in tumor immunotherapy.
J Hematol Oncol. 2020 Aug 3;13(1):107. doi: 10.1186/s13045-020-00939-6.
7
Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer.
Int Rev Cell Mol Biol. 2024;382:145-179. doi: 10.1016/bs.ircmb.2023.07.006. Epub 2023 Aug 12.
8
Wnt Signaling Cascade in Dendritic Cells and Regulation of Anti-tumor Immunity.
Front Immunol. 2020 Feb 17;11:122. doi: 10.3389/fimmu.2020.00122. eCollection 2020.
9
Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade.
Clin Exp Metastasis. 2024 Aug;41(4):333-349. doi: 10.1007/s10585-023-10257-z. Epub 2024 Jan 23.
10
Strategies to overcome DC dysregulation in the tumor microenvironment.
Front Immunol. 2022 Oct 6;13:980709. doi: 10.3389/fimmu.2022.980709. eCollection 2022.

引用本文的文献

3
Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis.
Front Immunol. 2024 Nov 4;15:1481296. doi: 10.3389/fimmu.2024.1481296. eCollection 2024.
4
Immune-Related Long Non-Coding RNA Signature Determines Prognosis and Immunotherapeutic Coherence in Esophageal Cancer.
Cancer Inform. 2024 Sep 12;23:11769351241276757. doi: 10.1177/11769351241276757. eCollection 2024.
6
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy.
Cancer Commun (Lond). 2024 Sep;44(9):1047-1070. doi: 10.1002/cac2.12596. Epub 2024 Jul 25.
7
Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma.
NPJ Precis Oncol. 2024 May 16;8(1):101. doi: 10.1038/s41698-024-00601-1.
8
Dendritic Cells in Cancer Immunology and Immunotherapy.
Cancers (Basel). 2024 Feb 28;16(5):981. doi: 10.3390/cancers16050981.

本文引用的文献

2
Visualization of immediate immune responses to pioneer metastatic cells in the lung.
Nature. 2016 Mar 24;531(7595):513-7. doi: 10.1038/nature16985. Epub 2016 Mar 16.
3
Mutanome directed cancer immunotherapy.
Curr Opin Immunol. 2016 Apr;39:14-22. doi: 10.1016/j.coi.2015.12.001. Epub 2015 Dec 21.
4
Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling.
Cell Rep. 2015 Dec 29;13(12):2851-64. doi: 10.1016/j.celrep.2015.11.053. Epub 2015 Dec 17.
5
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
Cancer Cell. 2015 Dec 14;28(6):690-714. doi: 10.1016/j.ccell.2015.10.012.
6
Immune suppressive mechanisms in the tumor microenvironment.
Curr Opin Immunol. 2016 Apr;39:1-6. doi: 10.1016/j.coi.2015.10.009. Epub 2015 Nov 21.
7
PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB.
Cancer Res. 2016 Jan 15;76(2):239-50. doi: 10.1158/0008-5472.CAN-15-0748. Epub 2015 Nov 13.
8
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.
Science. 2015 Nov 20;350(6263):972-8. doi: 10.1126/science.aad0779. Epub 2015 Oct 29.
9
Subversion of anticancer immunosurveillance by radiotherapy.
Nat Immunol. 2015 Oct;16(10):1005-7. doi: 10.1038/ni.3236.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验